Royal Philips has announced an update to its handheld ultrasound platform—Lumify—adding Pulse Wave Doppler technology to expand the haemodynamic assessment and measurement capabilities of the system.
In a press release, Philips said that the new functionality would enable clinicians to quantify blood flow in a wide range of point-of-care diagnostic applications including cardiology, vascular, abdominal, urology, obstetrics and gynecology.
Pulse Wave Doppler ultrasound provides clinicians with more information, in addition to 2D and colour imaging, to assess haemodynamic patterns to differentiate between arterial and venous blood flow and quantify haemodynamic function, Philips detailed in a press release. An additional update to the system includes obstetric measurements to help in early assessment of gestational age and the identification of high-risk pregnancies.
“By applying Philips’ expertise in cardiovascular care, imaging and patient monitoring to Philips Handheld Ultrasound—Lumify—we are committed to deliver a dedicated, innovative point-of-care portfolio, enabling clinicians to quickly assess haemodynamics—including cardiovascular function, organ perfusion and fetal assessment—in a daily routine, to identify abnormalities and intervene quickly,” said Matthijs Groot Wassink, general manager of Point of Care Ultrasound at Philips. “With the addition of Pulse Wave Doppler and enhanced obstetrics measurements, we have increased the number of markers on which diagnoses can be made, to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real-time.”
“Having Colour Flow Doppler (CFD) and Pulse Wave Doppler on a handheld device is game changing, allowing clinicians to take point-of-care ultrasound examinations to the next level,” said Robert Jones, professor of Emergency Medicine at the MetroHealth System, Cleveland, USA.
